Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Eikon TherapeuticsEIKN -3.40%12 Quick Ratio is 11.75 as of Mar. 2026, which is 34% above its 10-year median of 8.80. GuruFocus rates EIKN with a GF Score™ of 12/100. Among 1,411 Biotechnology companies, Eikon Therapeutics ranks better than 82.07% on this metric.
Eikon Therapeutics has a quick ratio of 11.75. It generally indicates good short-term financial strength.
The historical rank and industry rank for Eikon Therapeutics's Quick Ratio or its related term are showing as below:
EIKN'
s Quick Ratio Range Over the Past 10 Years
Min: 4.04 Med: 8.8 Max: 13.88
Current: 11.75
During the past 3 years, Eikon Therapeutics's highest Quick Ratio was 13.88. The lowest was 4.04. And the median was 8.80.
EIKN's Quick Ratio is ranked better than 82.07% of 1411
companies
in the Biotechnology industry
Industry Median: 3.59
vs EIKN: 11.75
Eikon Therapeutics (NAS:EIKN) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
Eikon Therapeutics Quick Ratio Related Terms
Eikon Therapeutics Quick Ratio Historical Data
* Premium members only.
The historical data trend for Eikon Therapeutics's Quick Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Eikon Therapeutics's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Eikon Therapeutics Quick Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Eikon Therapeutics's Quick Ratio distribution charts can be found below:
* The bar in red indicates where Eikon Therapeutics's Quick Ratio falls into.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
Eikon Therapeutics's Quick Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Eikon Therapeutics (EIKN) has a Quick Ratio of 11.75 as of Mar. 2026. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Eikon Therapeutics and its competitors. This is 34% above median its historical median of 8.80. Over the past decade, Eikon Therapeutics' Quick Ratio has ranged from 4.04 to 13.88. According to the industry distribution chart, Eikon Therapeutics ranks #253 out of 1411 companies in the Biotechnology industry, placing it in the top 17.9%.
Is Eikon Therapeutics' Quick Ratio too high?
Eikon Therapeutics' current Quick Ratio of 11.75 is 34% above median its 10-year median of 8.80. Over the past 10 years, this metric has ranged from a low of 4.04 to a high of 13.88. The Biotechnology industry median Quick Ratio is 3.59. Eikon Therapeutics' value of 11.75 is 227.3% above this industry median. Based on the distribution chart, Eikon Therapeutics ranks #253 out of 1411 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Eikon Therapeutics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Eikon Therapeutics' Quick Ratio compare to PRME and CRMD?
According to the Biotechnology industry distribution chart, Eikon Therapeutics ranks #253 out of 1411 companies for Quick Ratio. This places Eikon Therapeutics in the top 18% of its industry — outperforming the majority of peers. The industry median Quick Ratio is 3.59. Eikon Therapeutics' value of 11.75 is 227.3% above this benchmark. Historically, Eikon Therapeutics' own Quick Ratio has ranged from 4.04 to 13.88 over the past decade. While the company's 10-year median is 8.80 vs. the industry median of 3.59, Eikon Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Biotechnology company?
The median Quick Ratio among Biotechnology companies is 3.59, based on 1,411 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Eikon Therapeutics's current Quick Ratio of 11.75 is 227.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Eikon Therapeutics and its competitors. For the Biotechnology industry, the median Quick Ratio is 3.59 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Eikon Therapeutics's current Quick Ratio is 11.75, which is 34% above median its own 10-year median of 8.80. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Eikon Therapeutics stock overvalued right now?
Eikon Therapeutics (EIKN) has a current Quick Ratio of 11.75. The current Quick Ratio is 11.75, which is 34% above median its 10-year median of 8.80 and 227.3% above the Biotechnology industry median of 3.59. Eikon Therapeutics' overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For Eikon Therapeutics (EIKN), the current Quick Ratio is 11.75 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Eikon Therapeutics Inc is a late-stage clinical biopharmaceutical company dedicated to building a world-wide , fully-integrated organization developing important, medicines to address serious unmet medical needs. It operates in a single operating segment, which is in the business of drug discovery leveraging its proprietary technology and clinical development of its product candidates. Its product candidates include: EIK1001, EIK1003, EIK1004, EIK1005, and EIK1006.
12GF Score
Get the complete analysis for EIKN
Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
EIKN has been successfully added to your 
